|
SU5416 in Treating Children With Recurrent or Progressive Brain Tumors Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about SU5416 in Treating Children With Recurrent or Progressive Brain Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. SU5416 in Treating Children With Recurrent or Progressive Brain Tumors Clinical research trials and SU5416 in Treating Children With Recurrent or Progressive Brain Tumors health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as SU5416 in Treating Children With Recurrent or Progressive Brain Tumors. SU5416 in Treating Children With Recurrent or Progressive Brain Tumors Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a SU5416 in Treating Children With Recurrent or Progressive Brain Tumors clinical trial. Human subjects frequently get the finest healthcare available for their SU5416 in Treating Children With Recurrent or Progressive Brain Tumors condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > SU5416 in Treating Children With Recurrent or Progressive Brain Tumors  SU5416 in Treating Children With Recurrent or Progressive Brain Tumors
SU5416 in Treating Children With Recurrent or Progressive Brain Tumors
For Condition: Brain Cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Pediatric Brain Tumor Consortium
Synopsis: RATIONALE: SU5416 may stop the growth of brain cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating children who have recurrent or progressive brain tumors.
Details: OBJECTIVES: I. Determine the qualitative and quantitative toxicity of SU5416 in pediatric patients with recurrent or progressive brain tumors. II. Determine the acute and chronic dose-limiting toxicity and cumulative toxicity of this regimen in these patients. III. Determine the maximum tolerated dose and pharmacokinetics of this regimen in this patient population. IV. Determine the effects of hepatic enzyme-inducing drugs, such as anticonvulsant agents, on the pharmacokinetics of this regimen in these patients. V. Determine the efficacy, in a preliminary manner, of this regimen in these patients. PROTOCOL OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to concurrent use of enzyme-inducing anticonvulsant drugs (yes vs no drugs or modest-induction drugs). Patients receive SU5416 IV over 1 hour twice a week for 6 weeks. Treatment repeats every 6 weeks for 17 courses (approximately 2 years) in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients in each stratum receive escalating doses of SU5416 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years. PROJECTED ACCRUAL: A total of 50 patients (25 per stratum) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /21 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven malignant recurrent or progressive brain tumor at initial presentation or at time of recurrence or progression for which no standard curative therapy exists; Histologic verification for brainstem gliomas may be waived - Bone marrow involvement allowed --Prior/Concurrent Therapy-- - Biologic therapy: More than 6 months since prior bone marrow transplantation; More than 1 week since prior growth factor(s) - Chemotherapy: At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered - Endocrine therapy: Concurrent dexamethasone allowed if dose stable for at least 1 week prior to study - Radiotherapy: More than 3 months since prior craniospinal irradiation greater than 24 Gy; More than 3 months since prior total body irradiation; More than 2 weeks since prior focal irradiation to symptomatic metastatic sites; No prior stereotactic radiosurgery; Concurrent total body irradiation allowed - Surgery: See Radiotherapy - Other: No other concurrent anticancer or experimental drug therapy; Concurrent anticonvulsant drugs allowed --Patient Characteristics-- - Age: 21 and under - Performance status: Karnofsky 60-100% - Life expectancy: More than 8 weeks - Hematopoietic: Absolute neutrophil count greater than 1,000/mm3*; Platelet count greater than 75,000/mm3*; Hemoglobin greater than 9 g/dL (*Transfusion independent) - Hepatic: Bilirubin normal for age; SGOT and SGPT less than 2.5 times normal for age; PT/PTT no greater than 1.2 times upper limit of normal; Albumin greater than 3 g/dL; No overt hepatic disease - Renal: Creatinine no greater than 1.5 times normal for age OR Glomerular filtration rate greater than 70 mL/min; No overt renal disease - Cardiovascular: No deep venous or arterial thrombosis within the past 3 months; No history of myocardial infarction, severe or unstable angina, or severe peripheral vascular disease; No overt cardiac disease; No prior cerebral bleeds - Pulmonary: No pulmonary embolism within the past 3 months; No overt pulmonary disease - Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception; No known allergies to paclitaxel or other agent that uses Cremophor EL; No uncontrolled infection; Neurological deficits allowed if stable for at least 1 week prior to study; Greater than 3rd percentile weight for height
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MarkKieran, Study Chair, Pediatric Brain Tumor Consortium
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
United States
Children's National Medical Center
Washington D.C., District of Columbia, 20010-2970
United States
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15213
United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
United States
Saint Jude Children's Research Hospital
Memphis, Tennessee, 38105-2794
United States
Baylor College of Medicine
Houston, Texas, 77030
United States
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington, 98105
United States
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94143-0128
United States
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Additional Information:
Study ID Numbers: CDR0000068179; PBTC-002
Study Start Date: August 2000
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006247
Other Brain Cancer Studies:
1. SU5416 in Treating Children With Recurrent or Progressive Brain Tumors
2. Phenylbutyrate in Treating Children With Progressive or Recurrent Cancer of the Central Nervous System
Related Studies:
Other Brain Cancer Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
SU5416 in Treating Children With Recurrent or Progressive Brain Tumors
|
|
|
|
|
|
|
|
